Literature DB >> 10782407

The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium.

H M Morsi1, M P Leers, W Jäger, V Björklund, M Radespiel-Tröger, H el Kabarity, M Nap, N Lang.   

Abstract

Expression of a neoepitope on cytokeratin 18, recognized by the monoclonal antibody M30, is an early indicator of apoptosis in epithelial cells. The aim of this study was to determine the equilibrium between apoptosis (M30), anti-apoptosis (bcl-2), and proliferation (Ki-67) in different endometrial conditions. Paraffin-embedded samples (n = 107), representing proliferative endometrium (18), secretory endometrium (19), postmenopausal endometrium (15), disordered proliferative endometrium (6), simple hyperplasia (12), complex hyperplasia (8), and endometrial adenocarcinoma (29), were evaluated immunohistochemically. The indirect streptavidin-biotin-horseradish peroxidase technique, with 3-amino-9-ethylcarbazole as the chromogen, was used to visualize the reactions. Proliferative endometrium showed high bcl-2 and Ki-67 expression levels with no M30. In the secretory phase, the balance was tipped in favor of M30 with a decrease of bcl-2 and Ki-67. Postmenopausal endometrium revealed high Ki-67 and bcl-2 expression levels and no M30. In complex hyperplasia, M30, bcl-2, and Ki-67 showed increased expression. In endometrial carcinoma, an increasing reactivity for M30 and Ki-67 was seen as the grade progressed. bcl-2 reacted weakly and only in grade 1 cancer. Immunohistochemistry facilitates the study of the expression of proteins related to cyclic endometrial activity. Interruption of these cyclic events is associated with specific disturbances in the expression patterns of these proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782407     DOI: 10.1097/00004347-200004000-00004

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

Review 1.  Apoptosis Detection Methods in Diagnosis of Cancer and Their Potential Role in Treatment: Advantages and Disadvantages: a Review.

Authors:  Amir Khodavirdipour; Motahareh Piri; Sarvin Jabbari; Shiva Keshavarzi; Reza Safaralizadeh; Mohammad Yousef Alikhani
Journal:  J Gastrointest Cancer       Date:  2021-01-04

2.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

3.  Expression of Bcl-2 and p53 at the fetal-maternal interface of rhesus monkey.

Authors:  Peng Wei; Xuan Jin; Xue-Sen Zhang; Zhao-Yuan Hu; Chun-Sheng Han; Yi-Xun Liu
Journal:  Reprod Biol Endocrinol       Date:  2005-01-14       Impact factor: 5.211

Review 4.  New concepts for an old problem: the diagnosis of endometrial hyperplasia.

Authors:  Peter A Sanderson; Hilary O D Critchley; Alistair R W Williams; Mark J Arends; Philippa T K Saunders
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

5.  Proliferation in Postmenopausal Endometrial Polyps-A Potential for Malignant Transformation.

Authors:  Lina Adomaitienė; Rūta Nadišauskienė; Mahshid Nickkho-Amiry; Arvydas Čižauskas; Jolita Palubinskienė; Cathrine Holland; Mourad W Seif
Journal:  Medicina (Kaunas)       Date:  2019-08-28       Impact factor: 2.430

6.  Overexpression Of ERβ Participates In The Progression Of Liver Cancer Via Inhibiting The Notch Signaling Pathway.

Authors:  Yiping Zhang; Benyi Yi; Xufeng Zhou; Yahua Wu; Lili Wang
Journal:  Onco Targets Ther       Date:  2019-10-22       Impact factor: 4.147

7.  Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Authors:  Sarah Kitson; Vanitha N Sivalingam; James Bolton; Rhona McVey; Mashid Nickkho-Amiry; Melanie E Powell; Alexandra Leary; Hans W Nijman; Remi A Nout; Tjalling Bosse; Andrew G Renehan; Henry C Kitchener; Richard J Edmondson; Emma J Crosbie
Journal:  Mod Pathol       Date:  2016-12-02       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.